The predicted minimum serum tremelimumab concentration in the novel single-dose regimen of 300 mg tremelimumab in combination with durvalumab was greater than the estimated tremelimumab concentration eliciting half-maximal increases in CD8+Ki67+ T cells, thus proving the substantial and relevant immune response after tremelimumab/durvalumab application in patients with unresectable HCC [97]. This evidence concerns the gene CD8A and hepatocellular carcinoma.